Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
APRE

APRE - Aprea Therapeutics Inc Stock Price, Fair Value and News

6.37USD+0.09 (+1.43%)Market Closed
Watchlist

Market Summary

USD6.37+0.09
Market Closed
1.43%

APRE Stock Price

View Fullscreen

APRE RSI Chart

APRE Valuation

Market Cap

23.8M

Price/Earnings (Trailing)

-1.79

Price/Sales (Trailing)

14.91

Price/Free Cashflow

-1.77

APRE Price/Sales (Trailing)

APRE Profitability

Return on Equity

-65.48%

Return on Assets

-51.56%

Free Cashflow Yield

-56.53%

APRE Fundamentals

APRE Revenue

APRE Earnings

Earnings (TTM)

-13.3M

Earnings Growth (Yr)

20.38%

Earnings Growth (Qtr)

1.67%

Breaking Down APRE Revenue

Last 7 days

-2.8%

Last 30 days

4.5%

Last 90 days

54.6%

Trailing 12 Months

-38.5%

How does APRE drawdown profile look like?

APRE Financial Health

Current Ratio

6.15

APRE Investor Care

Shares Dilution (1Y)

41.01%

Diluted EPS (TTM)

18.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000

Tracking the Latest Insider Buys and Sells of Aprea Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 23, 2023
seizinger bernd r.
acquired
-
-
500
-
Aug 23, 2023
henneman john b iii
acquired
-
-
500
-
Aug 23, 2023
duey marc
acquired
-
-
500
-
Aug 23, 2023
pamukcu rifat
acquired
-
-
500
-
Aug 23, 2023
grissinger michael
acquired
-
-
500
-
Aug 23, 2023
peters richard
acquired
-
-
500
-
Jun 07, 2023
seizinger bernd r.
bought
22,192
3.6809
6,029
-
Jun 06, 2023
seizinger bernd r.
bought
14,764
3.6294
4,068
-
Mar 09, 2023
gilad oren
acquired
-
-
4,000
president, ceo
Feb 27, 2023
hamill john p.
acquired
5,250
5.25
1,000
srvp/cfo/prin fin & acct ofcr

1–10 of 50

Which funds bought or sold APRE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
GROUP ONE TRADING, L.P.
unchanged
-
1,102
10,152
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
added
0.03
1,740
15,280
-%
Feb 14, 2024
Walleye Capital LLC
reduced
-2.86
30,928
376,000
-%
Feb 14, 2024
Creative Planning
sold off
-100
-105
-
-%
Feb 14, 2024
VANGUARD GROUP INC
added
26.87
49,118
163,034
-%
Feb 14, 2024
Royal Bank of Canada
added
13,788
206,000
207,000
-%
Feb 13, 2024
MORGAN STANLEY
added
18.24
20,253
80,925
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
reduced
-68.63
-4,704
2,576
-%
Feb 13, 2024
Sio Capital Management, LLC
unchanged
-
149,380
1,316,000
0.30%

1–10 of 25

Are Funds Buying or Selling APRE?

Are funds buying APRE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APRE
No. of Funds

Unveiling Aprea Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
sio capital management, llc
7.49%
280,000
SC 13G
Feb 07, 2024
hirschman orin
9.4%
349,300
SC 13G/A
Mar 03, 2023
hirschman orin
9.2%
345,000
SC 13G
Nov 15, 2022
healthcap vii, l.p.
4.5%
2,366,104
SC 13D/A
Jun 30, 2022
healthcap vii, l.p.
10.1%
2,366,104
SC 13D/A
Feb 14, 2022
redmile group, llc
0%
0
SC 13G/A
Feb 11, 2022
versant ventures v, llc
0.0%
0
SC 13G/A
Oct 15, 2021
healthcap vii, l.p.
11.2%
2,366,104
SC 13D/A
Oct 12, 2021
morgan stanley
0.9%
184,964
SC 13G/A
Mar 24, 2021
morgan stanley
5.1%
1,072,411
SC 13G

Recent SEC filings of Aprea Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 09, 2024
424B3
Prospectus Filed
Feb 07, 2024
SC 13G/A
Major Ownership Report
Feb 06, 2024
8-K
Current Report
Feb 05, 2024
424B3
Prospectus Filed
Feb 02, 2024
8-K
Current Report
Feb 02, 2024
EFFECT
EFFECT
Jan 26, 2024
S-3
S-3
Jan 26, 2024
8-K
Current Report
Jan 04, 2024
8-K
Current Report

Peers (Alternatives to Aprea Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aprea Therapeutics Inc News

Latest updates
Simply Wall St10 Jan 202408:00 am

Aprea Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q2
Revenue27.9%319250
Operating Expenses-1.5%3,8423,901
  S&GA Expenses1.2%1,7201,699
Net Income1.7%-3,204-3,259
Net Income Margin100.0%--14.12*
Free Cashflow30.2%-2,258-3,233
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-10.2%26.0029.0032.0030.0034.0041.0050.0057.0062.0072.0080.0093.0010311512513457.0060.0063.0066.00
  Current Assets-10.5%26.0029.0032.0030.0033.0040.0050.0057.0062.0071.0080.0092.0010211412513357.00--66.00
    Cash Equivalents-8.4%25.0028.0031.0029.0033.0039.0048.0053.0061.0070.0078.0089.0010111312313052.0061.0066.0066.00
  Net PPE5009.5%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00--0.00
Liabilities-100.0%-4.004.003.004.008.007.007.009.0011.0011.0015.0014.0015.0012.009.0010.008.007.005.00
  Current Liabilities5.4%4.004.004.003.004.008.007.007.009.0011.0011.0015.0014.0015.0012.009.0010.00--5.00
Shareholder's Equity-13.4%20.0023.0026.0026.0027.0026244.0050.0053.0061.0069.0077.0089.0010011312420.0020.0020.0020.00
  Retained Earnings-1.1%-304-301-298-293-291-287-189-181-173-163-153-144-128-116-99.93-90.53-77.46---62.47
  Additional Paid-In Capital0.0%33633533533032826224324123723523323123022922722620.00--20.00
Shares Outstanding0.1%4.004.004.003.002.001.001.001.001.001.001.001.001.00-------
Float------14.00---70.00---264------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations30.3%-2,241-3,216-2,979-4,020-6,592-8,902-5,495-10,178-8,233-7,751-11,522-13,199-11,423-9,638-7,541-14,742-2,793-4,975-4,197-3,851-
Cashflow From Investing-------------16.29725*2.00-12.16-14.47-10.25----
Cashflow From Financing---5,14099.00---1,660-----12130.0091,198-3,619-4355,43356,365-

APRE Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Condensed Consolidated Statements of Operations and Comprehensive Loss    
Grant revenue$ 319,468 $ 569,156 
Operating expenses:    
Research and development2,122,603$ 1,117,5765,581,802$ 15,870,867
General and administrative1,719,7153,082,6186,784,38818,849,549
Acquired in-process research and development   76,020,184
Total operating expenses3,842,3184,200,19412,366,190110,740,600
Loss from operations(3,522,850)(4,200,194)(11,797,034)(110,740,600)
Other income:    
Interest income, net321,215151,123913,846205,585
Foreign currency gain(2,880)24,35339,686315,130
Total other income318,335175,476953,532520,715
Net loss(3,204,515)(4,024,718)(10,843,502)(110,219,885)
Other comprehensive loss:    
Foreign currency translation(1,002)26,161(12,466)118,311
Total comprehensive loss$ (3,205,517)$ (3,998,557)$ (10,855,968)$ (110,101,574)
Net loss per share attributable to common stockholders, basic (in dollars per share)$ (0.86)$ (2.32)$ (3.03)$ (83.33)
Net loss per share attributable to common stockholders, diluted (in dollars per share)$ (0.85)$ (2.32)$ (3.03)$ (83.33)
Weighted-average common shares outstanding, basic (in shares)3,735,1761,732,7833,577,4821,322,652
Weighted-average common shares outstanding, diluted (in shares)3,731,5711,732,7833,576,2681,322,652

APRE Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 25,353,513$ 28,786,647
Prepaid expenses and other current assets286,2631,366,859
Total current assets25,639,77630,153,506
Property and equipment, net86,1982,321
Restricted cash40,449 
Total assets25,766,42330,155,827
Current liabilities:  
Accounts payable862,552842,754
Accrued expenses3,303,5102,358,332
Total current liabilities4,166,0623,201,086
Commitments and contingencies (Note 8)
Stockholders' equity:  
Common stock, $0.001 par value, 400,000,000 shares authorized, 3,736,673 and 2,655,269 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively.3,7362,655
Additional paid-in capital335,561,343330,060,836
Accumulated other comprehensive loss(10,635,874)(10,623,408)
Accumulated deficit(304,639,907)(293,796,405)
Total stockholders' equity20,289,29825,643,678
Total liabilities and stockholders' equity25,766,42330,155,827
Series A Convertible Preferred Stock  
Convertible preferred stock:  
Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 56,227 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively.$ 1,311,063$ 1,311,063
APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
 CEO
 WEBSITEwww.aprea.com
 EMPLOYEES9

Aprea Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aprea Therapeutics Inc? What does APRE stand for in stocks?

APRE is the stock ticker symbol of Aprea Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aprea Therapeutics Inc (APRE)?

As of Thu Feb 22 2024, market cap of Aprea Therapeutics Inc is 23.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APRE stock?

You can check APRE's fair value in chart for subscribers.

What is the fair value of APRE stock?

You can check APRE's fair value in chart for subscribers. The fair value of Aprea Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aprea Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APRE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aprea Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APRE is over valued or under valued. Whether Aprea Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aprea Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APRE.

What is Aprea Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, APRE's PE ratio (Price to Earnings) is -1.79 and Price to Sales (PS) ratio is 14.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APRE PE ratio will change depending on the future growth rate expectations of investors.